Edwards Lifesciences (NYSE:EW) Trading Up 5.6% – Here’s Why

Edwards Lifesciences Corporation (NYSE:EW) shares shot up 5.6% during trading on Tuesday . The company traded as high as $80.01 and last traded at $80.1130. 1,287,108 shares were traded during trading, a decline of 71% from the average session volume of 4,384,525 shares. The stock had previously closed at $75.87.

Analyst Ratings Changes

EW has been the subject of a number of research reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Evercore reissued an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Stock Performance

The firm has a 50-day simple moving average of $83.17 and a two-hundred day simple moving average of $81.06. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $45.49 billion, a price-to-earnings ratio of 42.84, a price-to-earnings-growth ratio of 1.99 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares of the company’s stock, valued at $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 43,804 shares of company stock worth $3,699,082 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after buying an additional 4,805,819 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares during the period. Marshall Wace LLP boosted its stake in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares during the last quarter. Finally, Viking Global Investors LP bought a new position in Edwards Lifesciences in the third quarter valued at approximately $238,688,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.